Predictors and clinical significance of the positive cone margin in cervical intraepithelial neoplasia III patients

Size: px
Start display at page:

Download "Predictors and clinical significance of the positive cone margin in cervical intraepithelial neoplasia III patients"

Transcription

1 Chinese Medical Journal 2009;122(4): Original article Predictors and clinical significance of the positive cone margin in cervical intraepithelial neoplasia III patients SUN Xiao-guang, MA Shui-qing, ZHANG Jin-xia and WU Ming Keywords: conization; cervical intraepithelial neoplasia; factor analysis I Background Conization is being widely accepted for diagnosis and treatment of cervical intraepithelial neoplasia (CIN). There is controversy as to which factors are most predictive of a positive cone margin and the clinical significance of it. We conducted this study to identify the predictive factors and to evaluate the clinical significance of a positive cone margin in CIN III patients. Methods A retrospective review was conducted of 207 patients who had undergone conization due to CIN III from January 2003 to December 2005 at Peking Union Medical College Hospital. Of these, 67 had a subsequent hysterectomy. Univariate and multivariate analysis were utilized to define the predictive factors for a positive cone margin, and to compare the pathologic results of conization with subsequent hysterectomy. Results One hundred and fifty-one (72.9%) were margin free of CIN I or worse, 37 (17.9%) had CIN lesions close to the margin and 19 (9.2%) had margin involvement. A total of 56 cases (27.1%) had positive cone margins (defined as the presence of CIN at or close to the edge of a cone specimen). Univariate analysis showed that the parity, cytological grade, multi-quadrants of CIN III by punch biopsy, gland involvement, as well as the depth of conization were significant factors correlated with a positive cone margin (P <0.05). However the age, gravidity, grade of dysplasia in punch biopsy, as well as the cone methods were not significantly correlated (P >0.05). Multivariate analysis revealed that the cytological grade (OR=1.92), depth of conization (OR=2.03), parity (OR=3.02) and multi-quadrants of CIN III (OR=4.60) were significant predictors with increased risk for positive margin. The frequency of residual CIN I or worse in hysterectomy specimens was found to be 55.6% (20/36) in patients who were margin free, 71.4% (15/21) in patients with CIN occurring close to margin, and 80.0% (8/10) in patients with margin involvement. The frequency of residual CIN III or worse was found to be 13.9% (5/36), 23.8% (5/21) and 50.0% (5/10) respectively in different groups. Conclusions Cytological grade, depth of conization, parity and multi-quadrants of CIN III in punch biopsy were significant factors with increased risk in predicting a positive cone margin. Margin status of conization did not mean the presence or absence of CIN, but rather the varied frequency of residual CIN in specimens of subsequent hysterectomy. In view of this fact, it is suggested that the margin status of conization be a valuable surrogate marker for clinical management of CIN III. n recent years, an increased prevalence of cervical intraepithelial neoplasia (CIN) has been observed worldwide. Cervical conization, as both a diagnostic and therapeutic procedure, has been used for more than one hundred years and was popularized recently in the management of patients with CIN. 1 Conization shows special value with younger patients because it preserves reproductive function. Great attention had been focused on the possibility of complete excision of a CIN lesion by conization. In this study, we reviewed patients undergoing cervical conization for CIN III or worse with the objective to: identify the pre-operative predictors of a positive cone margin and evaluate the significance of positive cone margin in the management of CIN by analysis of residual disease present in specimens obtained upon subsequent hysterectomy. METHODS Patient enrollment Between January 2003 and December 2005, 240 patients received conization in the Department of Obstetrics and Gynecology, Peking Union Medical College Hospital. Of those, 33 were excluded in this study because of incomplete medical records (17 cases) and preoperative diagnosis of CIN II (16 cases). The medical records of the remaining 207 patients with CIN III or worse were retrospectively reviewed for analysis. Preoperative diagnosis was based on the histological result of colposcopically directed biopsy (punch biopsy). The median age, gravidity and parity of 207 patients were 37 (range ) years, 3 (range 0 9) times and 1 (range 0 5) time, respectively. DOI: /cma.j.issn Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing , China (Sun XG, Ma SQ, Zhang JX and Wu M) Correspondence to: Dr. SUN Xiao-guang, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing ,China ( xgsqc@vip.sina. com)

2 368 Diagnostic procedure before conization Preoperative examination followed a three-step technique, e.g. cytological test, colposcopy with punch biopsy and histological diagnosis. 2 In our study, 195 cases underwent thinprep cytological test (TCT), and the results were reported according to the 2001 Bethesda System. 3 Nine received a Papanicolaou smear and 3 were without cytological examination. The indication for colposcopy followed the 2001 consensus guidelines for the management of women with cervical cytological abnormalities 4 with small modification: (1) TCT showed ASC-US with positive high risk types of HPV by Hybrid Capture 2 test. (2) 2 repeat ASC-US at 3 6 month intervals. (3) TCT showed LSIL or higher than LSIL. (4) Grade III by Pap smear. In our study, 204 patients received colposcopy with punch biopsy (98.5%), of those 96 (47.1%) had colposcopy in our hospital. The remaining 108 patients (52.9%) were examined at other hospitals. Three cases received an immediate biopsy without colposcopy because of cervical polyps, two of them were given a pathological diagnosis of CIN III, and the third was diagnosed as carcinoma in situ (CIS). All 207 patients had histological results prior to conization. The pathologic slides from other hospitals were reviewed by two senior pathologists in our hospital. The cervical quadrants were divided by two straight lines through the orifice of the cervix, one line was from 1:30 to 7:30 of the cervix, and the other line was drawn perpendicular to the first line. Three or more quadrants involved by CIN III or by CINIII in the gland were defined as multi-quadrant involvement. Conization and pathology Two types of conization were performed, 142 patients (68.6%) underwent electrosurgical needle conization, whereas 65 (31.4%) received cold knife conization. For each method, the ectocervical edge of the cone was located 0.5 cm outside of the iodine negative area. The depth of the cone varied according to patients age, reproductive desire, the location of the transformational zone and purpose of the cone (diagnostic or therapeutic). The depth of cone with 1.5 cm was seen in 46 patients (22.2%), cm in 89 patients (43.0%), cm in 61 patients (29.5%), 2.6 cm in all other patients (5.3%). A fresh specimen was marked by a thread at 12 o clock for orientation. The specimen was prepared and evaluated at the department of pathology, Peking Union Medical College Hospital. After measurement of cone width and depth, the specimen was fixed in 13% formalin for 5 to 12 hours and sectioned radially from 1 12 o clock. The pathologic report was made within 72 hours and included the following information: the grade of dysplasia (CINI CINIII, CIS, microinvasive and invasive carcinoma), the location of lesions and the numbers of cervical quadrants involved, the endocervical gland involvement, the endocervical and ectocervical marginal status, as well as the width and depth of the cone specimen. Management after conization Clinical management following the conization procedure depended on the grade of dysplasia, cone margin status, reproductive desire, patients age, as well as the compliance with follow-up. The options of postcone management included: follow-up, re-conization, hysterectomy and radical hysterectomy. The indications for hysterectomy were: (1) post-menopausal women with CIN III or CIS. (2) patients with CIN III or worse with large myoma or other benign uterine disease, without reproductive desire. (3) patients with positive cone margin and without reproductive desire. (4) patients with cervical adenocarcinoma in situ or microinvasive squamous carcinoma. 5 In our study group, a total of 67 patients received hysterectomy or radical hysterectomy. Of those, 48 patients received laparoscopical total hysterectomy, 5 laparoscopically-assisted vaginal hysterectomy, 10 total abdominal hysterectomy and 4 radical hysterectomy. The median time of hysterectomy was 72 hours post- conization (range days), 94.0% (63/67) of patients received hysterectomy within 60d after conization. Among 140 patients who did not undergo hysterectomy after conization, reconization was undertaken in two patients who had a positive cone margin but with reproductive desire. The remaining 138 patients received close follow-up (cytology, HPV test and colposcopy) with a schedule of 3 6 months intervals in the initial two years and 6-month intervals in the third year after conization. Statistical analysis The demographic data (patients age, gravidity, parity), cytological results, pathologic parameters on punch biopsy (grade of disease, quadrants involved by CIN III, endocervical glands involvement ) and operative factors (methods and depth of cone) for all patients with CIN III were analyzed retrospectively. A negative margin was defined as the absence of CIN at the edge of the cone and a positive margin was judged by the presence of CIN at or close to ( 0.1 cm) the edge of the cone. Initially, we used chi-square test for univariable analysis. After excluding insignificant factors, multivariable logistic regression analysis were utilized for testing remaining factors, positive and negative cone margins were dependent variables. Finally, four factors were selected as significant in predicting the positive margin. A regression model was constructed by these four factors. The pathologic result of a cone was compared to the subsequent hysterectomy. The chi-square test was utilized to compare the residual CIN in uterine specimens among three groups of patients with different cone margin status: 36 patients with margins free of CIN, 21 patients with CIN occurring close to margins and 10 patients with margin involvement. A two-tailed P value <0.05 was considered statistically significant. For all statistical analysis, the statistical package for the social sciences for windows 11.5 (SPSS11.5) was used.

3 Chinese Medical Journal 2009;122(4): RESULTS Histological study of 207 cone specimens revealed that there were 5 cases (2.4%) with CINI, 30 cases (14.5%) with CINII, 120 cases (58.0%) with CINIII, 37 cases (17.9%) with cervical carcinoma in situ, 12 cases (5.8%) with microinvasive carcinoma and 3 cases (1.4%) with invasive carcinoma. Of 207 patients, 151 (72.9%) had cone margins free of CIN, 37 (17.9%) had CIN lesions close to the margins ( 0.1cm to margin) and 19 (9.2%) had margin involvement by CINI or a worse condition. The frequency of a positive margin was 27.1% (56/207). A positive endocervical margin was present in 43 cases (76.8%, 43/56), of which 14 had margin involvement and 29 had CIN close to the margin. A positive ectocervical margin was present in 10 cases (17.9%, 10/56), of which 2 had margin involvement and 8 had CIN occurring close to the margin. In addition, there were 3 cases (5.4%, 3/56) in which both endocervical and ectocervical margins were involved by CIN. In Table 1, we tested whether there was a correlation between positive cone margin status and various factors with univariable chi-square analysis. We found that age, gravidity, grade of disease by punch biopsy and the conization method were not significantly correlated with a positive cone margin (P >0.05), whereas parity, cytological grade, number of quadrants involving CIN III, multi-quadrant gland involvement and depth of cone had a significant correlation with a positive cone margin (P <0.05). In Table 1, 6 cases of ASC-H were classified into the HSIL group, of which 3 cases had a positive cone margin. The 12 cases who had no TCT result were excluded from the analysis of correlation between cytological result and positive cone margin. We further analyzed the correlation of operative factors to a positive cone margin, and found that the depth of the cone was a significant predictor for a positive endocervical margin, but the width of the cone was not statistically significant (data not shown) in predicting a positive ectocervical margin (P >0.05). The latter conclusion was based on the fact that the positive ectocervical margins were seen in 9 out of 143 cases (6.3%) with a cone width 2.5 cm, and 4 out of 64 cases (6.3%) with cone width 2.6 cm. Although five factors were well-correlated with a positive cone margin by univariable analysis, an integrated effect of these factors may be more valuable in predicting a positive cone margin. Table 2 outlines the result of multivariable logistic regression analysis of these five factors. Four factors, e.g. parity, cytological result, multi-quadrant CIN III and depth of cone had significant predictive values. The multi-quadrant endocervical gland involvement was also valuable, but this factor was excluded in the multivariable logistic regression model because of its high correlation with multi-quadrant CIN III (r=0.91, P <0.01). In Table 2, each significant factor Table 1. Correlation of clinical and histological factors with positive cone margin for CIN III patients Clinical and histological factors n No. of positive margin (%) P values * Age (years) (17.4) (27.7) (29.6) (25.0) Gravidity 3 times (24.7) times (34.7) Parity 1 time (24.9) times 18 9 (50.0) Cytology LSIL (18.4) HSIL (30.3) Pap smear grade III and immediate biopsy 12 6 (50.0) CIN III quadrants by punch biopsy 1 quadrant 55 9 (16.4) quadrants (25.0) 3 quadrants (35.4) 4 quadrants 19 9 (47.4) No record 17 4 (23.5) Grade of disease by punch biopsy CIN III/CIS (26.6) Micro-invasive carcinoma 15 5 (33.3) Quadrants of gland involvement by punch biopsy (18.4) (24.6) (54.5) (61.5) No record 17 4 (23.5) Methods of conization Electrosurgical conization (30.3) Cold-knife conization (20.0) Depth of conization (cm) (32.6) (19.3) * : Univariate, chi-square test. : Percentage of positive endocervial margin. : Statistically significant. Table 2. Predictive factors for positive cone margin by multivariate logistic regression analysis Factors B (Partial regression P OR coefficient) values (95% CI) Standard Parity 1 time * 2 times ( ) Cytology LSIL * HSIL ( ) CIN III quadrants by punch biopsy 1 * ( ) ( ) ( ) Depth of conization (cm) 1.6 * ( ) * : As a reference category. was subdivided into 2 4 categories, the category which was least correlated to a positive margin was chosen as the reference. Every other category had its own partial regression coefficient B and odds ratio, reflecting the

4 370 Table 3. Pathology of cone margin vs hysterectomy specimens (n (%)) Margin status Margin free (n=151) Margin closed by CIN (n=37) Margin involvement (n=19) Total (n=207) No. of hysterectomy Pathology of hysterectomy specimen No disease 16 (44.4) 6 (28.6) 2 (20.0) 24 (35.8) CIN I 20 (55.6) 15 (71.4) 8 (80.0) 43 (64.2) CIN I 8 (22.2) 3 (14.3) 1 (1/10) 12 (17.9) CIN II 7 (19.4) 7 (33.3) 2 (2/10) 16 (23.9) CIN III/CIS 4 (11.1) 4 (19.0) 3 (3/10) 11 (16.4) Micro-invasive and invasive carcinoma 1 (1/36) 1 (1/21) 2 (2/10) 4 (5.9) extent of the causal relation between the category and positive margin. The OR for cytological grade, depth of cone, parity and multi-quadrant CIN III were 1.92, 2.03, 3.02 and 4.60, respectively, thereby demonstrating an increased risk for a positive margin. Of 207 patients who underwent conization, 67 had a subsequent hysterectomy, including 36 cases with the margin free, 21 cases with the margin close to CIN and 10 cases with margin involvement. Table 3 shows a histological comparison of different cone margin status to hysterectomy specimens. The incidence of residual CIN I or worse in hysterectomy specimens for 67 cases was 64.2% (43/67), residual CIN III or worse was 22.4% (15/67). Furthermore, we found that the incidence of residual CIN I or worse was 55.6% (20/36) in the margin free group, 71.4% (15/21) in the group with CIN close to the margin and 80.0% (8/10) in the group with margin involvement. The incidence of residual CIN III or worse was found to be 13.9% (5/36), 23.8% (5/21) and 50% (5/10), respectively. The frequency of residual CIN III or worse in the margin free group was statistically lower than that of the two other groups (P <0.05). However, a significant difference was not found between the latter two groups (P >0.05). Five patients in the margin free group were found to have CIN III or worse in subsequent hysterectomy specimen, of which 3 were shown to have 3 quadrants of CIN III in punch biopsy or cone specimen. One patient had a cervical polyp with histological diagnosis of squamous carcinoma in situ and another patient was suspected of carcinoma in situ by TCT and diagnosed as microinvasive carcinoma by pathology of the cone specimen; in the latter case, the depth of the cone was <1 cm. DISCUSSION According to 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ, 6 excisional treatment, such as conization, is an acceptable method for the histological diagnosis of CIN III, under the conditions of both satisfactory or unsatisfactory colposcopy. As both a diagnostic and therapeutic procedure, conization provides a reasonable approach for clinical treatment, particularly for women who are young or wish to preserve fertility function. Although the indication and value of conization has been described previously, it was largely unknown whether it could be used for complete excision of CIN, and what factors known prior to surgery would be used in predicting the possibility of complete excision. The predictive factors we identify in this paper may be helpful for estimating the possibility of complete excision of CIN prior to conization and may serve as a guide during the operation in judging the width and depth of the cone. These factors also provide an important reference for preparing a suitable follow-up plan. Excisional methods that provide tissue specimens for pathology include loop electrosurgical excisional procedures (LEEP), electrosurgical needle conization, laser conization or cold-knife cone (CKC), all modalities having equivalent efficacy in eliminating CIN and reducing the risk of future cervical cancer. 6,7 Preoperative predictors for positive margins of different types of conization were discussed in several papers recently and are the subject of some controversy. For example, evidence of invasive carcinoma on LEEP specimen or on cytology, less than 1 cm of cone depth, as well as post-menopause were significant predictors for any cone margin involvement. 8 Parity was thought important as a predictor 7 and visibility of the squamous-columar junction was inversely related to the positive endocevical margin. 9 Our results revealed that cytological grade, depth of cone, parity, as well as multi-quadrant CIN III on punch biopsy were significant predictors with an increased risk for positive margins. Whereas age, gravity, severity of disease of specimens from punch biopsy and the method of cone excision were not significant determinants. These findings are therefore at variance with other studies. A CIN lesion is characterized by a multi-focal and multi-step development with a slow rate of progress. The different lesions on one cervix may show varied extents of severity, and may be caused by different types of HPV infection having different periods of duration. 10 Multiquadrant CIN and multi-quadrant gland involvement are generally the result of a prolonged period and severe HPV infection, and therefore show a high frequency of positive margins. Women with increased parity are more likely to have a positive margin, which was inferred as rapid progress during pregnancy and labor. 7 A high grade cytological result paralleled generally a high grade histological lesion and therefore was valuable in predicting positive margins. As for the depth of conization, some authors suggested that 1.5 cm is acceptable, 11 while others thought that 2.0 cm to 2.5 cm may be more appropriate. 5 We recommend that the depth of conization be tailored to the patient s condition. An

5 Chinese Medical Journal 2009;122(4): increased depth of conization will produce a satisfactory excision for menopausal women or women with unsatisfactory colposcopy because CIN lesion may be located deeper in the cervical canal under these conditions. In our study, the grade of dysplasia on punch biopsy was not confirmed to be a statistically significant factor, although the frequency of a positive cone margin increased as the grade of dysplasia increased. This correlation may have resulted because the sample pool of microinvasive carcinoma used in our study was not large enough to achieve a statistically significant result. A recent report found that the positive cone margin was also related to a surgeon s training. 12 Another study showed that the load of high risk HPV was a risk factor for predicting residual or recurrent dysplasia. 13 The value of high risk HPV load in predicting a positive cone margin cannot be confirmed by this study because our study was retrospective and the data was limited. The relationship between high risk HPV load and a positive cone margin needs to be confirmed by a more randomized and prospective study. The relationship of a positive margin status and residual or recurrent CIN has been of great concern. A number of studies revealed a cure rate of 42% 68% post-conization despite margin involvement. 14 A previous study noted that 5 out of 19 cases (26.3%) with cone margin involvement had no CIN in specimens obtained following subsequent hysterectomy. 12 Moore et al 15 found residual CIN in 32% of hysterectomy specimens having a negative cone margin, and an occasional invasive cancer was identified in such patients. 16 The facts above indicate that margin status does not always correlate with the presence or absence of CIN in specimens of subsequent hysterectomy. In the present study, the frequency of residual CIN was gradually increased in groups with different margin status: 55.6% in patients who were margin-free, compared with 71.4% in patients with CIN occurring close to the margin and 80.0% in patients with margin involvement. Our data demonstrate that the cone margin status reflects a variable frequency of residual CIN in patients who undergo subsequent hysterectomy. This outcome is perhaps the true value of cone margin status as a surrogate indicator for the management of CIN. Although the status of CIN close to the margin is frequently met by clinicians, its significance as an indicator of residual CIN in subsequent hysterectomy specimen is controversial. Our study demonstrate that the frequency of residual CIN is intermediate between the status of margin free and margin involvement, and did not show a significant difference with that of margin involvement status by chi-square test (P >0.05). This result explains why patients with CIN close to the margin were put into the positive margin group in our analysis. Because a different cone margin status represented a varied frequency of residual CIN, a close follow-up is necessary for patients without subsequent hysterectomy after conization regardless of the cone margin status. Reich et al 17 evaluated the outcome of a mean of 19 years of follow-up for 390 patients with involved margins after cold knife conization, 84 (21.5%) had persistent or recurrent CIN III or invasive carcinoma, of which 53 (63.1%) were diagnosed within 1 year after conization. This finding reinforced the importance of a careful follow-up, particularly during the first year. 17 The present study led us to identify four risk factors that were statistically valuable in predicting a positive margin prior to conization for CIN III patients. This conclusion will enable clinicians to estimate the surgical outcome before conization, and to address the question of complete excision of the CIN lesions by conization. We conclude that the margin status of the cone does not mean the presence or absence of CIN, but rather may suggest the varied frequency of residual CIN in specimens of subsequent hysterectomy. In view of this fact, we maintain that the margin status of a cone is a valuable surrogate factor for clinical management of CIN III. It is inferred therefore that a combined consideration of four predictive factors, the margin status of the cone, as well as high risk HPV load would be valuable in predicting the residual, persistent and recurrent dysplasia following conization. Additional clinical trials are needed to support this inference. Acknowledgement: The authors thank Dr. Susan A. Rotenberg at Queens College, City University of New York for her help in the preparation of this manuscript. REFERENCES 1. Shen K, Lang JH, Huang HF, Wu M, Shi M, Pan LY, et al. Evaluation of cervical conization in diagnosis and management of cervical intraepithelial neoplasm. Chin J Gynecol Obstet (Chin) 2001; 36: Song XH. Application of three-stage diagnosis and treatment process in screening, diagnosis and treatment of cervical precancerous lesions. Chin J Pract Gynecol Obstet (Chin) 2007; 23: Solomon D, Davey D, Kurman R, Moriarty A, O Connor D, Prev M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287: Shen K. Choices among the iatrotechnics for cervical intraepithelial neoplasia. Natl Med J China (Chin) 2006; 86: Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Soloman D consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007; 197: Tillmanns TD, Falkner CA, Engle DB, Wan JY, Mannel RS,

6 372 Walker JL, et al. Preoperative predictors of positive margins after loop electrosurgical excisional procedure-cone. Gynecologic Oncology 2006; 100: Kietpeerakool C, Srisomboon J, Ratchusiri K. Clinicopathologic predictors of incomplete excision after loop electrosurgical excision for cervical preneoplasia. Asia Pac J Cancer Prev 2005; 6: Costa S, De Nuzzo M, Terzano P, Santini D, De Simone P, Bovicelli A, et al. Factors associated with cone margin involvement in CIN patients undergoing conization-equivalent electrosurgical procedure. Acta Obstet Gynecol Scand 2000; 79: Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer 2007; 2: Micheal S Baggish. Treatment of Cervical Intra-epithelial Neoplasia. In: Micheal S Baggish. Colposcopy of the cervix, vagina, and vulva: a comprehensive textbook. Pennsylvania: Mosby, an affiliate of Elsevier Science (USA) 2003; Dai ZQ, Pan LY, Huang HF, Lang JH. Evaluation of cervical intraepithelial neoplasia positive cutting edge after conization. Chin J Oncol (Chin) 2007; 29: Alonso I, Torné A, Puig-Tintoré LM, Esteve R, Quinto L, Campo E, et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 2006; 103: Lu CH, Liu FS, Kuo CJ, Chang CC, Ho ES. Prediction of persistence or recurrence after conization for cervical intraepithelial neoplasia III. Obstet Gynecol 2006; 107: Moore BC, Higgins RV, Laurent SL, Marroum MC, Bellitt P. Predictive factors from cold knife conization for residual cervical intraepithelial neoplasia in subsequent hysterectomy. Am J Obstet Gynecol 1996; 174: Husseinzadeh N, Shbaro L, Wesseler T. Predictive value of cone margins and post-cone endocervical curettage with residual disease in subsequent hysterectomy. Gynecol Oncol 1989; 33: Reich O, Lahousen M, Pickel H, Tamussino K, Winter R. Cervical intraepithelial neoplasia III: long-term follow-up after cold-knife conization with involved margins. Obstet Gynecol 2002; 99: (Received June 20, 2008) Edited by CHEN Li-min

Cervical Cancer Screening Guideline

Cervical Cancer Screening Guideline Cervical Cancer Screening Guideline Prevention 2 Abbreviations Used 2 Specimen Collection Techniques 3 Screening 4 Management Women 21 Years and Older Pap results 5 findings: ASC-US and LSIL 6 findings:

More information

The society for lower genital tract disorders since 1964.

The society for lower genital tract disorders since 1964. The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology

More information

Explanation of your PAP smear

Explanation of your PAP smear Explanation of your PAP smear Approximately 5-10% of PAP smears in the United States are judged to be abnormal. Too often, the woman who receives this news worries that she already has, or will develop,

More information

Cervical Cancer The Importance of Cervical Screening and Vaccination

Cervical Cancer The Importance of Cervical Screening and Vaccination Cervical Cancer The Importance of Cervical Screening and Vaccination Cancer Cells Cancer begins in cells, the building blocks that make up tissues. Tissues make up the organs of the body. Sometimes, this

More information

American Academy of Family Physicians

American Academy of Family Physicians American Academy of Family Physicians Barbara E. Stanford MD Grand Rapids Family Medicine Residency Wege Family Medicine HPV is transient in most women HPV-75% Normal ASCUS LSIL HSIL Cancer 80-90% 75%???

More information

PROPERTY OF ELSEVIER SAMPLE CONTENT - NOT FINAL ABNORMAL PAP SMEAR (ABNORMAL CERVICAL CYTOLOGIC FINDINGS) Kathleen Dor

PROPERTY OF ELSEVIER SAMPLE CONTENT - NOT FINAL ABNORMAL PAP SMEAR (ABNORMAL CERVICAL CYTOLOGIC FINDINGS) Kathleen Dor 1 ABNORMAL PAP SMEAR (ABNORMAL CERVICAL CYTOLOGIC FINDINGS) Kathleen Dor Cervical cytology screening has significantly decreased rates of mortality from cervical cancer; however, 400 women die each year

More information

Cancer of the Cervix

Cancer of the Cervix Cancer of the Cervix WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 A woman's cervix (the opening of the uterus) is lined with cells. Cancer of the cervix occurs when those cells change,

More information

Understanding. Cervical Changes A Health Guide for Women. National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Understanding. Cervical Changes A Health Guide for Women. National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Cancer Institute Understanding Cervical Changes A Health Guide for Women U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health This guide helped me talk with my doctor after

More information

Management of Abnormal PAP Smears. K Chacko, MD, FACP 2010 GIM Conference

Management of Abnormal PAP Smears. K Chacko, MD, FACP 2010 GIM Conference Management of Abnormal PAP Smears K Chacko, MD, FACP 2010 GIM Conference Scope of the Problem About 7-10% 7 of PAPs will come back abnormal 3.5 to 4 million in the US each year Approximate 4000 deaths

More information

Management of Abnormal Pap Smear Clinical Practice Guideline

Management of Abnormal Pap Smear Clinical Practice Guideline Management of Abnormal Pap Smear Clinical Guideline General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method

More information

GUIDELINE DOCUMENT CERVICAL CANCER SCREENING IN SOUTH AFRICA 2015

GUIDELINE DOCUMENT CERVICAL CANCER SCREENING IN SOUTH AFRICA 2015 GUIDELINE DOCUMENT CERVICAL CANCER SCREENING IN SOUTH AFRICA 2015 Cervical cancer remains an important cause of morbidity and mortality in South Africa. At present the national cervical cancer prevention

More information

Cervical Cancer Screening and Management Guidelines: Changing Again, Huh?

Cervical Cancer Screening and Management Guidelines: Changing Again, Huh? Cervical Cancer Screening and Management Guidelines: Changing Again, Huh? Summary of 2013 recommendations from ASC (American Cancer Society), ASCCP (American Society for Colposcopy and Cervical Pathology),

More information

Cervical Cancer Screening. Clinical Practice Guidelines for Average Risk Women

Cervical Cancer Screening. Clinical Practice Guidelines for Average Risk Women QEYGYN051 Cervical Cancer Screening Clinical Practice Guidelines for Average Risk Women For Approval of the Provincial Medical Affairs Committee October 2013 Table of Contents Page Background Information

More information

NATIONAL GUIDELINE FOR CERVICAL CANCER SCREENING PROGRAMME

NATIONAL GUIDELINE FOR CERVICAL CANCER SCREENING PROGRAMME NATIONAL GUIDELINE FOR CERVICAL CANCER SCREENING PROGRAMME CERVICAL CANCER Introduction Cancer of the cervix is the second most common form of cancer amongst South African women. Approximately one in every

More information

THE RATIONALE FOR HYSTERECTOMY AFTER UTERINE CERVIX CONIZATION

THE RATIONALE FOR HYSTERECTOMY AFTER UTERINE CERVIX CONIZATION FACTA UNIVERSITATIS Series: Medicine and Biology Vol.4, No, 2007, pp. 25-29 UC 68.46-006-089-085 THE RATIONALE FOR HYSTERECTOMY AFTER UTERINE CERVIX CONIZATION Vekoslav Lilić, Zorica Stanojević 2, Biljana

More information

Cervical Cancer Screening

Cervical Cancer Screening Clinical in Oncology Cervical Cancer Screening V.1.2009 Continue www.nccn.org Panel Members * Edward E. Partridge, MD/Chair University of Alabama at Birmingham Comprehensive Cancer Center Nadeem Abu-Rustum,

More information

Cervical Cancer Prevention and Early Detection What is cervical cancer?

Cervical Cancer Prevention and Early Detection What is cervical cancer? Cervical Cancer Prevention and Early Detection What is cervical cancer? Cervical cancer starts in cells lining the cervix. The cervix is the lower part of the uterus (womb). It is sometimes called the

More information

Cervical Screening and HPV Vaccine Guidelines In Saudi Arabia. Prof. Mohammed Addar Chairmen Gyneoncology section KKUH, King Saud University

Cervical Screening and HPV Vaccine Guidelines In Saudi Arabia. Prof. Mohammed Addar Chairmen Gyneoncology section KKUH, King Saud University Cervical Screening and HPV Vaccine Guidelines In Saudi Arabia Prof. Mohammed Addar Chairmen Gyneoncology section KKUH, King Saud University Burden of HPV related cancers l l Cervical Cancer of the cervix

More information

The Cervical Screening Manual

The Cervical Screening Manual The Cervical Screening Manual A Guide for Health Departments and Providers Collaboration Partners: Chronic Disease and Injury Section Breast and Cervical Cancer Control Program Women s and Children s Health

More information

Colposcopic Management of Abnormal Cervical Cytology and Histology

Colposcopic Management of Abnormal Cervical Cytology and Histology No. 284, December 2012 Colposcopic Management of Abnormal Cervical Cytology and Histology This clinical practice guideline has been prepared by the Executive Council of the Society of Canadian Colposcopists

More information

Office Visits. Breast

Office Visits. Breast Early Detection Works Reimbursement Fee Schedule Effective for services on or after July 1, 2015 Program guidelines require that be the payor of last resort. Program funds cannot be used to supplement

More information

Abnormal Pap Smear Tracking in General Internal Medicine Clinic

Abnormal Pap Smear Tracking in General Internal Medicine Clinic Abnormal Pap Smear Tracking in General Internal Medicine Clinic J A C O B K U R L A N D E R & T A R A O B R I E N C A R Q I P R O J E C T J A N U A R Y 2 0, 2 0 1 0 PDSA cycle Plan Act Do Study Our Charge

More information

Invasive Cervical Cancer. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology

Invasive Cervical Cancer. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Invasive Cervical Cancer Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Etiology Human Papilloma Virus (HPV): Detected in 99.7% of cervical cancers Cancer

More information

Pap smears, cytology and CCHC lab work and follow up

Pap smears, cytology and CCHC lab work and follow up Pap smears, cytology and CCHC lab work and follow up What is a Pap Smear? A Pap smear (also known as the Pap test) is a medical procedure in which a sample of cells from a woman's cervix (the end of the

More information

Sage Screening Program. Provider Manual

Sage Screening Program. Provider Manual Sage Screening Program Provider Manual Sage Screening Program Minnesota Department of Health 85 E. 7th Place, Suite 400 P.O. Box 64882 St. Paul, Minnesota 55164-0882 (651) 201-5600 (phone) (651) 201-5601-

More information

worry When to Cervical Abnormalities CME Workshop What s the situation? What are the trends? By Dianne Miller, MD, FRCSC In this article:

worry When to Cervical Abnormalities CME Workshop What s the situation? What are the trends? By Dianne Miller, MD, FRCSC In this article: CME Workshop When to worry Cervical Abnormalities By Dianne Miller, MD, FRCSC What s the situation? Over 600,000 Papanicolaou s (Pap) smears were performed in British Columbia in 2000. Approximately 13,400

More information

FRIEND TO FRIEND CPT CODES 2015 2016. Diagnostic digital breast tomosynthesis, unilateral (list separately in addition to code for primary procedure)

FRIEND TO FRIEND CPT CODES 2015 2016. Diagnostic digital breast tomosynthesis, unilateral (list separately in addition to code for primary procedure) FRIEND TO FRIEND CPT CODES 2015 2016 CPT CODE SERVICE DESCRIPTION FEE EFFECTIVE G0101 Screening pelvic examination $36.69 01 Jan 16 G0202 Mammography, screening, digital, bilateral (2 view film study of

More information

Cervical Cancer Screening

Cervical Cancer Screening TOC NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Cervical Cancer Screening Version 2.2012 NCCN.g Continue Version 2.2012, 05/02/12 National Comprehensive Cancer Netwk, Inc. 2012, All

More information

HPV, Cervical Dysplasia and Cancer

HPV, Cervical Dysplasia and Cancer FACTSHEET HPV, Cervical Dysplasia and Cancer Summary Cervical dysplasia is an abnormal change in the cells of the cervix in the uterus. Early changes, called low-grade lesions by doctors, may persist and

More information

Examples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.

Examples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening. CANCER SCREENING Dr. Tracy Sexton (updated July 2010) What is screening? Screening is the identification of asymptomatic disease or risk factors by history taking, physical examination, laboratory tests

More information

2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors

2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors L. Stewart Massad, MD, Mark H. Einstein, MD, Warner K. Huh, MD, Hormuzd A. Katki,

More information

HUMAN PAPILLOMAVIRUS (HPV) FACT SHEET

HUMAN PAPILLOMAVIRUS (HPV) FACT SHEET HUMAN PAPILLOMAVIRUS (HPV) FACT SHEET Background Information - Human Papillomavirus HPV is the name of a group of viruses that include more than 80 different types associated with a variety of epidermal

More information

Provider Reimbursement for Women's Cancer Screening Program

Provider Reimbursement for Women's Cancer Screening Program Reimbursement Schedule July 1, 2015 June 30, 2016 Office Visits - Established Patients Office Visit / Minimal / no physician 99211 $ 16.70 Office Visit / Problem focused History / exam 99212 $ 36.46 Preventive

More information

Saturation Biopsy for Diagnosis and Staging of Prostate Cancer. Original Policy Date

Saturation Biopsy for Diagnosis and Staging of Prostate Cancer. Original Policy Date MP 7.01.101 Saturation Biopsy for Diagnosis and Staging of Prostate Cancer Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date /12/2013 Return to Medical Policy

More information

Why I don t recommend endometrial ablation

Why I don t recommend endometrial ablation Why I don t recommend endometrial ablation Endometrial ablation is a major operative procedure that: o Is ineffective because, according to all research, 40% will ultimately still need a hysterectomy,

More information

ALABAMA BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM PROVIDER MANUAL

ALABAMA BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM PROVIDER MANUAL ALABAMA BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM PROVIDER MANUAL Revised January 2012 1 TABLE OF CONTENTS PROGRAM OVERVIEW.. 3 INTRODUCTION 5 SCREENING ELIGIBILITY GUIDELINES 6 PATIENT RIGHTS..

More information

XI International Workshop of Lower Genital Tract Pathology HPV Disease: The global battle Rome 19-21 April 2012

XI International Workshop of Lower Genital Tract Pathology HPV Disease: The global battle Rome 19-21 April 2012 XI International Workshop of Lower Genital Tract Pathology HPV Disease: The global battle Rome 19-21 April 2012 Thursday 19 nd April 2012 Morning Sessions 07.50-08.20 Registration 08.20-08.40 Welcome:

More information

HUMAN PAPILLOMAVIRUS (HPV) TESTING

HUMAN PAPILLOMAVIRUS (HPV) TESTING MEDICAL POLICY HUMAN PAPILLOMAVIRUS (HPV) TESTING Policy Number: CDP - 041 Effective Date: October 1, 2014 Table of Contents Page BACKGROUND 1 POLICY 3 REFERENCES 5 POLICY HISTORY/REVISION HISTORY 7 INSTRUCTIONS

More information

How To Compare The Effects Of A Hysterectomy And A Hysterectomy

How To Compare The Effects Of A Hysterectomy And A Hysterectomy A RANDOMIZED TRIAL COMPARING RADICAL HYSTERECTOMY AND PELVIC NODE DISSECTION VS SIMPLE HYSTERECTOMY AND PELVIC NODE DISSECTION IN PATIENTS WITH LOW RISK EARLY STAGE CERVICAL CANCER A Gynecologic Cancer

More information

GLOBAL CONCERNS ABOUT HPV VACCINES FACT SHEET

GLOBAL CONCERNS ABOUT HPV VACCINES FACT SHEET GLOBAL CONCERNS ABOUT HPV VACCINES FACT SHEET When detected, HPV infection is easily managed and rarely proceeds to cancer Very few women with HPV develop cervical cancer HPV infections are only one of

More information

HPV testing in the follow-up of women post colposcopy treatment

HPV testing in the follow-up of women post colposcopy treatment HPV testing in the follow-up of women post colposcopy treatment Contents Background 2 Treatment of CIN and risk of recurrence 2 The natural history of HPV infections 2 HPV testing for women following

More information

Building Awareness of Cervical Cancer

Building Awareness of Cervical Cancer Building Awareness of Cervical Cancer Guest Expert: Peter, MD John Slade Ely Professor of Obstetrics, Gynecology & Reproductive Sciences www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center

More information

Cervical Cancer. Cervical smear test. The cervix. Dysplasia. Cervical cancer. The female reproductive system

Cervical Cancer. Cervical smear test. The cervix. Dysplasia. Cervical cancer. The female reproductive system INFORMATION SHEET Cervical Cancer This information sheet has been written to provide you with information about cervical cancer (cancer of the cervix). The sheet has information about the different types

More information

2015 RN.ORG, S.A., RN.ORG, LLC

2015 RN.ORG, S.A., RN.ORG, LLC Cervical Cancer WWW.RN.ORG Reviewed September, 2015, Expires September, 2017 Provider Information and Specifics available on our Website Unauthorized Distribution Prohibited 2015 RN.ORG, S.A., RN.ORG,

More information

CERVICAL CHANGES UNDERSTANDING A HEALTH GUIDE FOR WOMEN. family EDUCATION PATIENT. National Institutes of Health National Cancer Institute

CERVICAL CHANGES UNDERSTANDING A HEALTH GUIDE FOR WOMEN. family EDUCATION PATIENT. National Institutes of Health National Cancer Institute UNDERSTANDING CERVICAL CHANGES A HEALTH GUIDE FOR WOMEN PATIENT & family EDUCATION U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute A Pap Test Showed

More information

HPV and the Future of Cervical Screening

HPV and the Future of Cervical Screening HPV and the Future of Cervical Screening John Tidy, Professor of Gynaecological Oncology Chair, National Colposcopy QA Committee, Sheffield What is HPV? Small ds DNA virus Over 140 genotypes described

More information

Cervical cancer in 2 women with a Mirena : a pitfall in the assessment of irregular bleeding

Cervical cancer in 2 women with a Mirena : a pitfall in the assessment of irregular bleeding Cervical cancer in 2 women with a Mirena : a pitfall in the assessment of irregular bleeding S. DE WEERD 1, P.J. WESTENEND 2, G.S. KOOI 1 1 Department of Obstetrics & Gynaecology, Albert Schweitzer Hospital,

More information

CXCA-MSP. The next step in cervical cancer prevention! GynTect : Epigenetic biomarkers for reliable cancer diagnostics. www.gbo.

CXCA-MSP. The next step in cervical cancer prevention! GynTect : Epigenetic biomarkers for reliable cancer diagnostics. www.gbo. CXCA-MSP The next step in cervical cancer prevention! GynTect : Epigenetic biomarkers for reliable cancer diagnostics www.gbo.com/diagnostics H 3 C NH 2 NH H 3 C 2 N mc N mc N H N O H O The challenge of

More information

An abnormal Pap smear - what does it mean?

An abnormal Pap smear - what does it mean? An abnormal Pap smear - what does it mean? It is natural to feel worried if you have just found out that your Pap smear result is not normal (abnormal). Around 1 in 10 Pap smears will show changes in the

More information

Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?

Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.

More information

Facing a Hysterectomy? If you ve been diagnosed with early stage gynecologic cancer, learn about minimally invasive da Vinci Surgery

Facing a Hysterectomy? If you ve been diagnosed with early stage gynecologic cancer, learn about minimally invasive da Vinci Surgery Facing a Hysterectomy? If you ve been diagnosed with early stage gynecologic cancer, learn about minimally invasive da Vinci Surgery The Condition: Early Stage Gynecologic Cancer A variety of gynecologic

More information

The Diagnosis of Cancer in the Pathology Laboratory

The Diagnosis of Cancer in the Pathology Laboratory The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens

More information

Historical Basis for Concern

Historical Basis for Concern Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical

More information

Summa Health System. A Woman s Guide to Hysterectomy

Summa Health System. A Woman s Guide to Hysterectomy Summa Health System A Woman s Guide to Hysterectomy Hysterectomy A hysterectomy is a surgical procedure to remove a woman s uterus (womb). The uterus is the organ which shelters and nourishes a baby during

More information

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone

More information

*DE-IDENTIFIED DEPOSITION OF A GYNECOLOGIST IN AN UNNECESSARY HYSTERECTOMY CASE* 2 SUPREME COURT OF THE STATE OF NEW YORK

*DE-IDENTIFIED DEPOSITION OF A GYNECOLOGIST IN AN UNNECESSARY HYSTERECTOMY CASE* 2 SUPREME COURT OF THE STATE OF NEW YORK *DE-IDENTIFIED DEPOSITION OF A GYNECOLOGIST IN AN UNNECESSARY HYSTERECTOMY CASE* 1 2 SUPREME COURT OF THE STATE OF NEW YORK 3 COUNTY OF BRONX --------------------------------------------- X 4 and, 5 Plaintiffs,

More information

How To Decide If You Should Get A Mammogram

How To Decide If You Should Get A Mammogram American Medical Women s Association Position Paper on Principals of Breast Cancer Screening Breast cancer affects one woman in eight in the United States and is the most common cancer diagnosed in women

More information

How To Treat A Uterine Sarcoma

How To Treat A Uterine Sarcoma EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition 2001 Uterus: Uterine Sarcomas Jeffrey L. Stern, MD Uterine sarcomas

More information

Biomedical Engineering for Global Health. Lecture Thirteen

Biomedical Engineering for Global Health. Lecture Thirteen Biomedical Engineering for Global Health Lecture Thirteen Outline The burden of cancer How does cancer develop? Why is early detection so important? Strategies for early detection Example cancers/technologies

More information

Making Sense of Your Pap and HPV Test Results

Making Sense of Your Pap and HPV Test Results Making Sense of Your Pap and HPV Test Results Keep this booklet until you get your test results back from your doctor. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention

More information

What is cervical cancer?

What is cervical cancer? What is cervical cancer? Cervical cancer is a term used for a tumour that starts in the cervix where the uterus (womb) meets the vagina (birth canal). The cells of the cervix don t suddenly turn into cancer;

More information

INTERVENTIONAL PROCEDURES PROGRAMME

INTERVENTIONAL PROCEDURES PROGRAMME NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of radical laparoscopic hysterectomy for early stage cervical cancer Introduction This overview

More information

SITUATIONAL ANALYSIS OF CERVICAL CANCER PREVENTION AND CONTROL IN THE CARIBBEAN

SITUATIONAL ANALYSIS OF CERVICAL CANCER PREVENTION AND CONTROL IN THE CARIBBEAN SITUATIONAL ANALYSIS OF CERVICAL CANCER PREVENTION AND CONTROL IN THE CARIBBEAN Results from a 2013 assessment of country policies and services for HPV vaccination, cervical cancer screening, diagnosis

More information

Carcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in

Carcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition, 2001 Vagina Jeffrey L. Stern, MD Carcinoma of the vagina is

More information

Cervical Cancer. What is cancer?

Cervical Cancer. What is cancer? What is cancer? Cervical Cancer The body is made up of trillions of living cells. Normal body cells grow, divide to make new cells, and die in an orderly way. During the early years of a person's life,

More information

Polyps. Hyperplasias. CAP 2011: Course AP104. The High Risk Benign Endometrium. Mutter and Nucci 1

Polyps. Hyperplasias. CAP 2011: Course AP104. The High Risk Benign Endometrium. Mutter and Nucci 1 Course AP104 Endometrial Hyperplasia A morphologic Definition Hyperplasias Hormonal Effect or Precancer? George L. Mutter, MD Harvard Medical School and Brigham and Women s Hospital Boston, MA Endometrial

More information

SCREENING FOR CANCER OF THE CERVIX

SCREENING FOR CANCER OF THE CERVIX SCREENING FOR CANCER OF THE CERVIX An Office Manual for Health Professionals This manual has been prepared by the Cervical Cancer Screening Program of the BC Cancer Agency to support effective use of the

More information

Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins

Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins The American Journal of Surgery 190 (2005) 521 525 George Peter s Award Winner Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins Heather R. MacDonald,

More information

What is neuroendocrine cervical cancer?

What is neuroendocrine cervical cancer? Key Points: 1. Neuroendocrine cancer of the uterine cervix is a rare and aggressive disease. 2. Treatment for neuroendocrine cervical cancer is usually more intensive than that for most other types of

More information

How HPV drives new cervical cancer screening guidelines

How HPV drives new cervical cancer screening guidelines How HPV drives new cervical cancer screening guidelines L. Stewart Massad, M.D. Dept. of Obstetrics & Gynecology Washington University School of Medicine St. Louis, MO Disclosure I do not have financial

More information

Colposcopy. Information for patients. Women s & Children s

Colposcopy. Information for patients. Women s & Children s Women s & Children s Colposcopy Information for patients Welcome to the gynaecology service at King s. The Colposcopy Unit is situated in Suite 8 of the Golden Jubilee Wing. The information in this leaflet

More information

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred

More information

Accent on Health Obgyn, PC HPV Frequently Asked Questions

Accent on Health Obgyn, PC HPV Frequently Asked Questions 1. What is HPV? 2. How do you get HPV? 3. How common is HPV? 4. What are the symptoms of HPV? 5. Can HPV be treated? 6. What is the HPV test and how is it different from a PAP test? 7. Can the HPV test

More information

Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com

Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com News Release FOR IMMEDIATE RELEASE Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com Merck's HPV Vaccine, GARDASIL 9, now available

More information

Why would you need a hysterectomy?

Why would you need a hysterectomy? Why would you need a hysterectomy? Removal of the uterus is performed to prevent, alleviate, or treat pain, pressure, bleeding, or cancer. Each reason is described in detail in the following pages. Benign

More information

Cost-Effectiveness of Office Hysteroscopy for Abnormal Uterine Bleeding

Cost-Effectiveness of Office Hysteroscopy for Abnormal Uterine Bleeding SCIENTIFIC PAPER Cost-Effectiveness of Office Hysteroscopy for Abnormal Uterine Bleeding Nash S. Moawad, MD, MS, Estefania Santamaria, BS, Megan Johnson, MD, Jonathan Shuster, PhD ABSTRACT Background and

More information

Pre test Question 2. Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013

Pre test Question 2. Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013 Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013 Objectives After completion of this presentation, the participant will be able to: Explain the current

More information

Gynecologic Cancer in Women with Lynch Syndrome

Gynecologic Cancer in Women with Lynch Syndrome Gynecologic Cancer in Women with Lynch Syndrome Sarah E. Ferguson, MD FRCSC Division of Gynecologic Oncology, Princess Margaret Hospital, University of Toronto June 11, 2013 Objective 1. To review the

More information

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths

More information

Captivator EMR Device

Captivator EMR Device Device Clinical Article and Abstract Summary Endoscopic Mucosal Bergman et al: EMR Training Tips Bergman et al: EMR Learning Curve ASGE: EMR & ESD Guidelines Bergman et al: Captivator EMR vs Cook Duette

More information

Testing for HPV as an Objective Measure for Quality Assurance in Gynecologic Cytology

Testing for HPV as an Objective Measure for Quality Assurance in Gynecologic Cytology 67 Testing for HPV as an Objective Measure for Quality Assurance in Gynecologic Cytology Positive Rates in Equivocal and Abnormal Specimens and Comparison With the ASCUS to SIL Ratio Vincent Ko, MD Shabin

More information

The Pap Smear: Guidelines for Screening and Follow-up

The Pap Smear: Guidelines for Screening and Follow-up The Pap Smear: Guidelines for Screening and Follow-up The incidence of and mortality from cervical cancers have decreased with the Pap smear's opportunistic use in Canada. The rate of decline has eased,

More information

NHS Cervical Screening Having a colposcopy

NHS Cervical Screening Having a colposcopy NHS Cervical Screening Having a colposcopy What is a colposcopy? 1 Why do I need a colposcopy? 1 What does a colposcopy involve? 2 Colposcopy results 4 Treatment to remove abnormal cells in the cervix

More information

Cervical Cancer. Understanding your diagnosis

Cervical Cancer. Understanding your diagnosis Cervical Cancer Understanding your diagnosis Cervical Cancer Understanding your diagnosis When you first hear that you have cancer, you may feel alone and afraid. You may be overwhelmed by the large amount

More information

OBJECTIVES By the end of this segment, the community participant will be able to:

OBJECTIVES By the end of this segment, the community participant will be able to: Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway

More information

Routine Vaginal Cuff Smear Testing in Post Hysterectomy Patients With Benign Uterine Conditions: When Is It Indicated?

Routine Vaginal Cuff Smear Testing in Post Hysterectomy Patients With Benign Uterine Conditions: When Is It Indicated? ORIGINAL ARTICLES Routine Vaginal Cuff Smear Testing in Post Hysterectomy Patients With Benign Uterine Conditions: When Is It Indicated? Andrea Videleftky, MD, Nonnan GrossI, MD, Maxine Denniston, MSPH,

More information

Cervical Cancer. Understanding your diagnosis

Cervical Cancer. Understanding your diagnosis Cervical Cancer Understanding your diagnosis Cervical Cancer Understanding your diagnosis When you first hear that you have cancer, you may feel alone and afraid. You may be overwhelmed by the large amount

More information

Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64

Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64 Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64 1. BMI - Documented in patients medical record on an annual basis. Screen for obesity and offer intensive counseling and behavioral

More information

Cervical Dysplasia and HPV.

Cervical Dysplasia and HPV. For Women Newly Diagnosed with Cervical Dysplasia and HPV. Sister Zeus 2009 www.sisterzeus.com A high percentage of women receiving the news that they have cervical dysplasia and that it could progress

More information

Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE

Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE Introduction This guide is designed to help you clarify and understand the decisions that need to be made about your care for the

More information

Overview of Gynaecologic Cancer

Overview of Gynaecologic Cancer Overview of Gynaecologic Cancer Stuart Salfinger Gynaecologic Oncologist St John of God Hospital King Edward Memorial Hospital Cervical Cancer Cervical Cancer Risk HPV Smoking?OCP Cervical Cancer Symptoms

More information

Treating heavy menstrual bleeding caused by fibroids or polyps

Treating heavy menstrual bleeding caused by fibroids or polyps Treating heavy menstrual bleeding caused by fibroids or polyps With today s medical advances the outlook for successful treatment of fibroids and polyps has never been better. You don t have to live with

More information

The Role of the Pap Smear Diagnosis: Atypical Glandular Cells (AGC)

The Role of the Pap Smear Diagnosis: Atypical Glandular Cells (AGC) 15 The Role of the Pap Smear Diagnosis: Atypical Glandular Cells (AGC) Chiung-Ru Lai 1,2, Chih-Yi Hsu 1,2 and Anna Fen-Yau Li 1,2 1 Department of Pathology and Laboratory Medicine, Taipei Veterans General

More information

4. Screening programs of cervical cancer

4. Screening programs of cervical cancer Transworld Research Network 37/661 (2), Fort P.O. Trivandrum-695 023 Kerala, India Recent Advances in Cervical Cancer, 2011: 45-54 ISBN: 978-81-7895-522-3 Editor: Iztok Takač 4. Screening programs of cervical

More information

Saturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies

Saturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies Saturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies John F. Ward, MD Assistant Professor University of Texas M. D. Anderson Cancer Center Ablation

More information

Creation Date: 12/24/2008. Effective Date: 07/14/2009 Date of Revision/Review: 07/14/2009 Version #:1 Date of Next Review: 07/14/2010

Creation Date: 12/24/2008. Effective Date: 07/14/2009 Date of Revision/Review: 07/14/2009 Version #:1 Date of Next Review: 07/14/2010 Site: Fremont Rideout Health Group Laboratory Services Policy and Procedure Creation Date: 12/24/2008 Subject/Title: Collection of Specimens for Conventional & ThinPrep Pap Tests, HPV Document Owner: Rogers,

More information

WOOD COUNTY SCHOOL OF PRACTICAL NURSING. Medical/Surgical Nursing: Reproductive

WOOD COUNTY SCHOOL OF PRACTICAL NURSING. Medical/Surgical Nursing: Reproductive WOOD COUNTY SCHOOL OF PRACTICAL NURSING Medical/Surgical Nursing: Reproductive Time: 19 Hours Theory; 1 Hour Pharmacology IV, (1 Diet Therapy - Integrated.) Placement: Nursing IV. Instructor: Toni Tennant,

More information

Hysterectomy. The time to take care of yourself

Hysterectomy. The time to take care of yourself Hysterectomy The time to take care of yourself The time to take care of yourself Women spend a lot of time taking care of others spouses, children, parents. We often overlook our own needs. But when our

More information

Further investigations, treatments and new technologies

Further investigations, treatments and new technologies Promoting Cervical Screening Information for Health Professionals Further investigations, treatments and new technologies Population Health Queensland Cancer Screening Services Branch Queensland Cervical

More information

A Cost Effectiveness Analysis of Cervical Cancer Screening in Sweden

A Cost Effectiveness Analysis of Cervical Cancer Screening in Sweden A Cost Effectiveness Analysis of Cervical Cancer Screening in Sweden Abstract The thesis deals with the problem of how to effectively minimize the prevalence of cervical cancer in Sweden. A cost effectiveness

More information